Identification

Name
Lovastatin
Accession Number
DB00227  (APRD00370)
Type
Small Molecule
Groups
Approved, Investigational
Description

Lovastatin is a cholesterol-lowering agent that belongs to the class of medications called statins. It was the second agent of this class discovered. It was discovered by Alfred Alberts and his team at Merck in 1978 after screening only 18 compounds over 2 weeks. The agent, also known as mevinolin, was isolated from the fungi Aspergillus terreus. Research on this compound was suddenly shut down in 1980 and the drug was not approved until 1987. Interesting, Akira Endo at Sankyo Co. (Japan) patented lovastatin isolated from Monascus ruber four months before Merck. Lovastatin was found to be 2 times more potent than its predecessor, mevastatin, the first discovered statin. Like mevastatin, lovastatin is structurally similar to hydroxymethylglutarate (HMG), a substituent of HMG-Coenzyme A (HMG-CoA), a substrate of the cholesterol biosynthesis pathway via the mevalonic acid pathway. Lovastatin is a competitive inhibitor of HMG-CoA reductase with a binding affinity 20,000 times greater than HMG-CoA. Lovastatin differs structurally from mevastatin by a single methyl group at the 6’ position. Lovastatin is a prodrug that is activated by in vivo hydrolysis of the lactone ring. It, along with mevastatin, has served as one of the lead compounds for the development of the synthetic compounds used today.

Structure
Thumb
Synonyms
  • (1S,3R,7S,8S,8AR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
  • 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone
  • 6-alpha-methylcompactin
  • 6alpha-Methylcompactin
  • 6α-methylcompactin
  • LOVASTATIN
  • Lovastatina
  • Lovastatine
  • Lovastatinum
  • Mevinolin
  • ML-530b
External IDs
C10AA02 / L-154803 / MK-803 / ML-530B
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LovastatinTablet40 mgOralActavis Pharma Company2004-07-28Not applicableCanada
Act LovastatinTablet20 mgOralActavis Pharma Company2004-07-28Not applicableCanada
AltoprevTablet, extended release20 mg/1OralShionogi2002-06-262017-12-31Us
AltoprevTablet, extended release20 mg/1OralCovis Pharma2016-05-01Not applicableUs
AltoprevTablet, extended release60 mg/1OralCovis Pharma2016-05-01Not applicableUs
AltoprevTablet, extended release60 mg/1OralShionogi2002-06-262016-12-31Us
AltoprevTablet, extended release40 mg/1OralShionogi2002-06-262018-02-28Us
AltoprevTablet, extended release40 mg/1OralCovis Pharma2016-05-01Not applicableUs
Ava-lovastatinTablet40 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-lovastatinTablet20 mgOralAvanstra Inc2011-08-182014-08-21Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lovastatin - Tab 20mgTablet20 mgOralApotex Corporation1997-03-27Not applicableCanada
Apo-lovastatin - Tab 40mgTablet40 mgOralApotex Corporation1997-03-27Not applicableCanada
LovastatinTablet40 mg/1OralGolden State Medical Supply2002-11-25Not applicableUs
LovastatinTablet20 mg/1OralRebel Distributors2007-11-01Not applicableUs
LovastatinTablet20 mg/1OralEon Labs, Inc.2001-12-17Not applicableUs
LovastatinTablet40 mg/1OralPhysicians Total Care, Inc.2003-04-14Not applicableUs
LovastatinTablet40 mg/1OralRemedy Repack2011-09-232016-10-13Us
LovastatinTablet10 mg/1Oralbryant ranch prepack2002-11-25Not applicableUs
LovastatinTablet20 mg/1OralBlenheim Pharmacal, Inc.2013-10-09Not applicableUs
LovastatinTablet20 mg/1OralAv Kare, Inc.2002-06-06Not applicableUs
International/Other Brands
Altocor / Mevacor
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AdvicorLovastatin (40 mg/1) + Niacin (1000 mg/1)Tablet, extended releaseOralAbbvie2001-12-172018-01-31Us
AdvicorLovastatin (20 mg/1) + Niacin (500 mg/1)Tablet, extended releaseOralPhysicians Total Care, Inc.2003-06-032017-03-11Us
AdvicorLovastatin (20 mg/1) + Niacin (750 mg/1)Tablet, extended releaseOralAbbvie2001-12-172017-04-30Us
AdvicorLovastatin (20 mg) + Niacin (500 mg)Tablet, extended release; Tablet, multilayer, extended releaseOralSepracor Pharmaceuticals Inc2005-11-092012-08-02Canada
AdvicorLovastatin (20 mg/1) + Niacin (1000 mg/1)Tablet, extended releaseOralAbbvie2001-12-172017-11-30Us
AdvicorLovastatin (40 mg) + Niacin (1000 mg)Tablet, extended release; Tablet, multilayer, extended releaseOralSepracor Pharmaceuticals Inc2007-05-152010-07-26Canada
AdvicorLovastatin (40 mg/1) + Niacin (1000 mg/1)Tablet, extended releaseOralPhysicians Total Care, Inc.2006-08-08Not applicableUs
AdvicorLovastatin (20 mg/1) + Niacin (500 mg/1)Tablet, extended releaseOralAbbvie2001-12-172018-03-31Us
AdvicorLovastatin (20 mg) + Niacin (1000 mg)Tablet, extended release; Tablet, multilayer, extended releaseOralSepracor Pharmaceuticals Inc2005-11-092012-08-02Canada
Categories
UNII
9LHU78OQFD
CAS number
75330-75-5
Weight
Average: 404.5396
Monoisotopic: 404.256274262
Chemical Formula
C24H36O5
InChI Key
PCZOHLXUXFIOCF-BXMDZJJMSA-N
InChI
InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
IUPAC Name
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
SMILES

Pharmacology

Indication

For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia. For primary prevention of coronary heart disease and to slow progression of coronary atherosclerosis in patients with coronary heart disease.

Structured Indications
Pharmacodynamics

The primary cause of cardiovascular disease is atherosclerotic plaque formation. Sustained elevations of cholesterol in the blood increase the risk of cardiovascular disease. Lovastatin lowers hepatic cholesterol synthesis by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. At therapeutic doses, lovastatin decreases serum LDL cholesterol by 29-32%, increases high density lipoprotein (HDL) cholesterol by 4.6-7.3%, and decrease triglyceride levels by 2-12%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.

Mechanism of action

Lovastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Lovastatin is a prodrug that is activated in vivo via hydrolysis of the lactone ring to form the β-hydroxyacid. The hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind to HMG-CoA reductase with 20,000 times greater affinity than its natural substrate. The bicyclic portion of lovastatin binds to the coenzyme A portion of the active site.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
NIntegrin alpha-L
other/unknown
Human
NHistone deacetylase 2
other
Human
Absorption

Studies suggest that <5% of the oral dose reaches the general circulation as active inhibitors. Time to peak serum concentration is 2-4 hours. Lovastatin undergoes extensive first-pass metabolism so the availability of the drug in the system is low and variable.

Volume of distribution

Lovastatin is able to cross the blood-brain-barrier and placenta.

Protein binding

Lovastatin and its β-hydroxyacid metabolites are highly protein bound (>95%).

Metabolism

Lovastatin is hepatically metabolized in which the major active metabolites are the β-hydroxyacid of lovastatin, the 6’-hydroxy derivative, and two additional metabolites.

Route of elimination

Lovastatin undergoes extensive first-pass extraction in the liver, its primary site of action, with subsequent excretion of drug equivalents in the bile. 83% of the orally administered dose is excreted in bile and 10% is excreted in urine.

Half life

5.3 hours

Clearance
Not Available
Toxicity

LD50>1000 mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Lovastatin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Lovastatin can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Lovastatin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Lovastatin can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AbafunginThe risk or severity of adverse effects can be increased when Abafungin is combined with Lovastatin.Investigational
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Lovastatin.Approved
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Lovastatin.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Lovastatin.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Lovastatin.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Lovastatin.Approved
AcetazolamideThe serum concentration of Lovastatin can be increased when it is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Lovastatin.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Lovastatin.Approved, Investigational
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Lovastatin.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Lovastatin.Approved
AlbaconazoleThe risk or severity of adverse effects can be increased when Albaconazole is combined with Lovastatin.Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Lovastatin.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Lovastatin.Approved
AldesleukinThe serum concentration of Lovastatin can be increased when it is combined with Aldesleukin.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Lovastatin.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Lovastatin.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Lovastatin.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Lovastatin.Approved
AlmasilateThe serum concentration of Lovastatin can be decreased when it is combined with Almasilate.Approved, Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Lovastatin.Approved, Investigational
AlogliptinThe serum concentration of Lovastatin can be increased when it is combined with Alogliptin.Approved
AloglutamolThe serum concentration of Lovastatin can be decreased when it is combined with Aloglutamol.Experimental
AlosetronThe metabolism of Alosetron can be decreased when combined with Lovastatin.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Lovastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Lovastatin.Approved, Illicit, Investigational
AluminiumThe serum concentration of Lovastatin can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Lovastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Lovastatin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Lovastatin can be decreased when it is combined with Aluminum hydroxide.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Lovastatin.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Lovastatin.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Lovastatin.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Lovastatin.Approved
AmiodaroneThe metabolism of Lovastatin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Lovastatin.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Lovastatin.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Lovastatin.Approved, Investigational
AmprenavirThe serum concentration of Lovastatin can be increased when it is combined with Amprenavir.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Lovastatin.Approved
AnastrozoleThe serum concentration of Lovastatin can be increased when it is combined with Anastrozole.Approved, Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Lovastatin.Approved
Antithrombin III humanThe serum concentration of Lovastatin can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Lovastatin.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Lovastatin.Approved, Investigational
AprepitantThe serum concentration of Lovastatin can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Lovastatin can be increased when it is combined with Aprotinin.Approved, Withdrawn
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Lovastatin.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Lovastatin.Approved, Investigational
ArgatrobanThe serum concentration of Lovastatin can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lovastatin.Approved, Investigational
Arsenic trioxideThe serum concentration of Lovastatin can be increased when it is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Lovastatin.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Lovastatin.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Lovastatin.Approved, Withdrawn
AsunaprevirThe serum concentration of Lovastatin can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Lovastatin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Lovastatin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Lovastatin is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Lovastatin.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Lovastatin.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Lovastatin.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Lovastatin.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Lovastatin.Investigational
AzithromycinAzithromycin may increase the myopathic rhabdomyolysis activities of Lovastatin.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Lovastatin.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Lovastatin.Approved
BatimastatThe serum concentration of Lovastatin can be increased when it is combined with Batimastat.Experimental
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Lovastatin.Approved
BenazeprilThe serum concentration of Lovastatin can be increased when it is combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Lovastatin.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Lovastatin.Approved, Investigational
BenzamidineThe serum concentration of Lovastatin can be increased when it is combined with Benzamidine.Experimental
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Lovastatin.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Lovastatin.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Lovastatin.Approved, Withdrawn
BetamethasoneThe serum concentration of Lovastatin can be increased when it is combined with Betamethasone.Approved, Vet Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Lovastatin.Approved, Investigational
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Lovastatin.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Lovastatin.Approved
BifonazoleThe serum concentration of Lovastatin can be increased when it is combined with Bifonazole.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Lovastatin can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Lovastatin can be decreased when it is combined with Bismuth subnitrate.Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Lovastatin.Approved
BivalirudinThe serum concentration of Lovastatin can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Lovastatin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Lovastatin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Lovastatin can be increased when combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Lovastatin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lovastatin.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Lovastatin.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Lovastatin.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Lovastatin.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Lovastatin.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Lovastatin.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Lovastatin.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Lovastatin.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Lovastatin.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Lovastatin.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Lovastatin.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Lovastatin.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Lovastatin.Approved, Investigational
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Lovastatin.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Lovastatin.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Lovastatin.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Lovastatin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Lovastatin.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Lovastatin.Approved, Nutraceutical
Calcium CarbonateThe serum concentration of Lovastatin can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Lovastatin can be decreased when it is combined with Calcium silicate.Experimental
CamostatThe serum concentration of Lovastatin can be increased when it is combined with Camostat.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Lovastatin.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Lovastatin.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Lovastatin.Approved
CandoxatrilThe serum concentration of Lovastatin can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Lovastatin can be increased when it is combined with Candoxatrilat.Experimental
CapsaicinThe serum concentration of Lovastatin can be increased when it is combined with Capsaicin.Approved
CaptoprilThe serum concentration of Lovastatin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Lovastatin can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Lovastatin.Approved
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Lovastatin.Vet Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Lovastatin.Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Lovastatin.Approved
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Lovastatin.Experimental
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Lovastatin.Approved, Investigational
CaspofunginThe serum concentration of Lovastatin can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Lovastatin.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Lovastatin.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Lovastatin.Approved, Vet Approved
CeritinibThe serum concentration of Lovastatin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Lovastatin.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Lovastatin.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Lovastatin.Approved
ChloramphenicolThe serum concentration of Lovastatin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Lovastatin.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Lovastatin.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Lovastatin.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Lovastatin.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Lovastatin.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Lovastatin.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Lovastatin.Approved, Nutraceutical
CholesterolThe serum concentration of Lovastatin can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Lovastatin can be increased when it is combined with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Lovastatin.Approved, Investigational
CilastatinThe serum concentration of Lovastatin can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Lovastatin can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lovastatin.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Lovastatin.Approved
CimetidineThe serum concentration of Lovastatin can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Lovastatin.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Lovastatin.Approved, Investigational
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Lovastatin.Approved, Investigational
CiprofloxacinThe serum concentration of Lovastatin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Lovastatin.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Lovastatin.Approved
ClarithromycinThe serum concentration of Lovastatin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Lovastatin can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Lovastatin.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Lovastatin.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Lovastatin.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Lovastatin.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Lovastatin.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Lovastatin.Investigational
ClomifeneThe serum concentration of Lovastatin can be increased when it is combined with Clomifene.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Lovastatin.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Lovastatin.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Lovastatin.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Lovastatin.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Lovastatin.Approved, Illicit
ClorindioneLovastatin may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Lovastatin.Approved, Illicit
ClotrimazoleThe metabolism of Lovastatin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Lovastatin.Approved
CobicistatThe serum concentration of Lovastatin can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Lovastatin.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Lovastatin.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Lovastatin.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Lovastatin.Approved
ConivaptanThe serum concentration of Lovastatin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Lovastatin.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Lovastatin.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Lovastatin.Approved
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Lovastatin.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Lovastatin.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Lovastatin.Approved, Investigational
CyclosporineThe serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Lovastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Lovastatin.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lovastatin.Approved
DabrafenibThe serum concentration of Lovastatin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Lovastatin can be increased when it is combined with Daclatasvir.Approved
DalfopristinThe serum concentration of Lovastatin can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Lovastatin can be increased when it is combined with Danazol.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Lovastatin.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Lovastatin.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Lovastatin.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Lovastatin.Approved, Investigational
DaptomycinThe risk or severity of adverse effects can be increased when Lovastatin is combined with Daptomycin.Approved, Investigational
DarexabanThe serum concentration of Lovastatin can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Lovastatin.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Lovastatin.Experimental
DarunavirThe serum concentration of Lovastatin can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Lovastatin.Approved
DasatinibThe serum concentration of Lovastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Lovastatin.Approved
DeferasiroxThe serum concentration of Lovastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Lovastatin.Approved
DelanzomibThe serum concentration of Lovastatin can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Lovastatin can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Lovastatin.Approved
DesipramineThe serum concentration of Lovastatin can be increased when it is combined with Desipramine.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Lovastatin.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Lovastatin.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Lovastatin.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Lovastatin.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Lovastatin.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Lovastatin.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Lovastatin.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Lovastatin.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Lovastatin.Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Lovastatin.Approved
DiethylstilbestrolThe serum concentration of Lovastatin can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Lovastatin.Approved, Investigational
DigoxinThe metabolism of Digoxin can be decreased when combined with Lovastatin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Lovastatin.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lovastatin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lovastatin.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Lovastatin.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Lovastatin.Approved
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Lovastatin.Approved
Dimethyl sulfoxideThe serum concentration of Lovastatin can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DiphenadioneLovastatin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Lovastatin.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Lovastatin.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Lovastatin.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Lovastatin.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Lovastatin.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Lovastatin.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Lovastatin.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Lovastatin.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Lovastatin.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Lovastatin.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Lovastatin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Lovastatin.Investigational
DoxepinThe metabolism of Doxepin can be decreased when combined with Lovastatin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lovastatin.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Lovastatin.Approved, Investigational
DoxycyclineThe metabolism of Lovastatin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Lovastatin.Approved, Illicit
DronedaroneThe serum concentration of Lovastatin can be increased when it is combined with Dronedarone.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Lovastatin.Approved, Investigational
EcabetThe serum concentration of Lovastatin can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe serum concentration of Lovastatin can be increased when it is combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Lovastatin.Approved
EfavirenzThe serum concentration of Lovastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Lovastatin.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Lovastatin.Approved, Investigational
ElafinThe serum concentration of Lovastatin can be increased when it is combined with Elafin.Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Lovastatin.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Lovastatin.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Lovastatin.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Lovastatin.Approved
EnalaprilThe serum concentration of Lovastatin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Lovastatin can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Lovastatin can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Lovastatin.Approved
EnzalutamideThe serum concentration of Lovastatin can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Lovastatin.Approved, Investigational
Epigallocatechin GallateThe serum concentration of Lovastatin can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Lovastatin.Approved, Investigational
EpinephrineThe serum concentration of Lovastatin can be increased when it is combined with Epinephrine.Approved, Vet Approved
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Lovastatin.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Lovastatin.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Lovastatin.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Lovastatin.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Lovastatin.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Lovastatin.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Lovastatin.Approved, Investigational
ErythromycinThe serum concentration of Lovastatin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Lovastatin.Approved, Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Lovastatin.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Lovastatin.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Lovastatin.Approved, Investigational
EstramustineThe metabolism of Estramustine can be decreased when combined with Lovastatin.Approved
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Lovastatin.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Lovastatin.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Lovastatin.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Lovastatin.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Lovastatin.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Lovastatin.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Lovastatin.Approved
Ethyl biscoumacetateLovastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Lovastatin.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Lovastatin.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Lovastatin.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Lovastatin.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Lovastatin.Approved, Investigational
EtravirineThe serum concentration of Lovastatin can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Lovastatin.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Lovastatin.Approved, Investigational
EzetimibeThe serum concentration of Lovastatin can be increased when it is combined with Ezetimibe.Approved
FaldaprevirThe serum concentration of Lovastatin can be increased when it is combined with Faldaprevir.Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Lovastatin.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Lovastatin.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Lovastatin.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Lovastatin.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Lovastatin.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Lovastatin.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Lovastatin.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lovastatin.Approved
FidaxomicinThe risk or severity of adverse effects can be increased when Fidaxomicin is combined with Lovastatin.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Lovastatin.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Lovastatin.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Lovastatin.Approved
FluconazoleThe serum concentration of Lovastatin can be increased when it is combined with Fluconazole.Approved
FluindioneLovastatin may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Lovastatin.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Lovastatin.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Lovastatin.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Lovastatin.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Lovastatin.Approved, Vet Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Lovastatin.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Lovastatin.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Lovastatin.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Lovastatin.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be decreased when combined with Lovastatin.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Lovastatin.Approved
FluvoxamineThe metabolism of Lovastatin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Lovastatin.Approved, Investigational
FosamprenavirThe serum concentration of Lovastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lovastatin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Lovastatin can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Lovastatin can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Lovastatin.Approved, Investigational
Fusidic AcidThe serum concentration of Lovastatin can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lovastatin.Approved, Investigational
GabexateThe serum concentration of Lovastatin can be increased when it is combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Lovastatin.Approved
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Lovastatin.Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Lovastatin.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Lovastatin.Approved, Investigational
GeldanamycinThe serum concentration of Lovastatin can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilGemfibrozil may increase the myopathic rhabdomyolysis activities of Lovastatin.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Lovastatin.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Lovastatin.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Lovastatin.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Lovastatin.Approved
Glycerol PhenylbutyrateThe serum concentration of Lovastatin can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GM6001The serum concentration of Lovastatin can be increased when it is combined with GM6001.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Lovastatin.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Lovastatin.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Lovastatin.Investigational, Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Lovastatin.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Lovastatin.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Lovastatin.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Lovastatin.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Lovastatin.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Lovastatin.Approved, Investigational
HydralazineThe serum concentration of Lovastatin can be increased when it is combined with Hydralazine.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Lovastatin.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Lovastatin.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Lovastatin.Approved, Illicit
HydrotalciteThe serum concentration of Lovastatin can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Lovastatin.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Lovastatin.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Lovastatin.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Lovastatin.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Lovastatin.Approved
IdelalisibThe serum concentration of Lovastatin can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Lovastatin can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Lovastatin resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Lovastatin.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Lovastatin.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Lovastatin.Approved, Investigational
ImidaprilThe serum concentration of Lovastatin can be increased when it is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Lovastatin.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Lovastatin.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Lovastatin.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Lovastatin.Approved
IndinavirThe serum concentration of Lovastatin can be increased when it is combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Lovastatin.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Lovastatin.Approved, Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Lovastatin.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Lovastatin.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Lovastatin.Approved, Investigational
IsavuconazoleThe risk or severity of adverse effects can be increased when Isavuconazole is combined with Lovastatin.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Lovastatin.Approved, Investigational
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Lovastatin.Approved
IsoflurophateThe serum concentration of Lovastatin can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Lovastatin can be increased when it is combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lovastatin.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Lovastatin.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Lovastatin.Approved
ItraconazoleThe serum concentration of Lovastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Lovastatin.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Lovastatin.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Lovastatin.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Lovastatin.Approved, Investigational
IxazomibThe serum concentration of Lovastatin can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Lovastatin can be increased when it is combined with Josamycin.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Lovastatin.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Lovastatin.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Lovastatin.Approved, Investigational
KetoconazoleThe serum concentration of Lovastatin can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Lovastatin.Approved, Vet Approved
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Lovastatin.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Lovastatin.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lovastatin.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Lovastatin.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Lovastatin.Approved
LapatinibThe metabolism of Lapatinib can be decreased when combined with Lovastatin.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Lovastatin.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Lovastatin.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Lovastatin.Approved, Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Lovastatin.Approved
LepirudinThe serum concentration of Lovastatin can be increased when it is combined with Lepirudin.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Lovastatin.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Lovastatin.Approved
LetaxabanThe serum concentration of Lovastatin can be increased when it is combined with Letaxaban.Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Lovastatin.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Lovastatin.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Lovastatin.Approved
LevofloxacinThe serum concentration of Lovastatin can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Lovastatin.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Lovastatin.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Lovastatin.Approved, Investigational
LevosalbutamolThe serum concentration of Lovastatin can be increased when it is combined with Levosalbutamol.Approved
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Lovastatin.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Lovastatin.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Lovastatin.Approved, Vet Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Lovastatin.Experimental
LinagliptinThe serum concentration of Lovastatin can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Lovastatin can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Lovastatin.Approved, Investigational
LomitapideThe serum concentration of Lovastatin can be increased when it is combined with Lomitapide.Approved
LomustineThe serum concentration of Lovastatin can be increased when it is combined with Lomustine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Lovastatin.Approved
LopinavirThe serum concentration of Lovastatin can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Lovastatin.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Lovastatin.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Lovastatin.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Lovastatin.Approved
LuliconazoleThe serum concentration of Lovastatin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Lovastatin can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Lovastatin.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Lovastatin.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Lovastatin.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Lovastatin.Illicit, Investigational, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Lovastatin.Approved
MagaldrateThe serum concentration of Lovastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Lovastatin.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe serum concentration of Lovastatin can be increased when it is combined with Manidipine.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Lovastatin.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Lovastatin.Approved, Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Lovastatin.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Lovastatin.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Lovastatin.Approved
MelagatranThe serum concentration of Lovastatin can be increased when it is combined with Melagatran.Experimental
MelatoninThe metabolism of Melatonin can be decreased when combined with Lovastatin.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Lovastatin.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Lovastatin.Investigational, Withdrawn
MequitazineThe serum concentration of Lovastatin can be increased when it is combined with Mequitazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Lovastatin.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Lovastatin.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Lovastatin.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Lovastatin.Illicit, Withdrawn
MethazolamideThe serum concentration of Lovastatin can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Lovastatin can be increased when it is combined with Methimazole.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Lovastatin.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
MethylergometrineThe serum concentration of Lovastatin can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Lovastatin.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Lovastatin.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Lovastatin.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Lovastatin.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Lovastatin.Approved
MetyraponeThe serum concentration of Lovastatin can be increased when it is combined with Metyrapone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Lovastatin.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Lovastatin.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Lovastatin.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Lovastatin.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Lovastatin.Approved, Illicit
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Lovastatin.Approved
MifepristoneThe serum concentration of Lovastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Lovastatin.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Lovastatin.Approved
MitotaneThe serum concentration of Lovastatin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Lovastatin can be increased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Lovastatin.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Lovastatin.Approved, Investigational
MoexiprilThe serum concentration of Lovastatin can be increased when it is combined with Moexipril.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Lovastatin.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Lovastatin.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Lovastatin.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Lovastatin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Lovastatin can be increased when it is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Lovastatin.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Lovastatin.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Lovastatin.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Lovastatin.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Lovastatin.Approved, Investigational
NefazodoneThe serum concentration of Lovastatin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lovastatin can be increased when it is combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Lovastatin.Approved, Investigational
NetupitantThe serum concentration of Lovastatin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Lovastatin can be increased when combined with Nevirapine.Approved
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Lovastatin.Approved, Investigational, Nutraceutical
NicardipineThe metabolism of Nicardipine can be decreased when combined with Lovastatin.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Lovastatin.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Lovastatin.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Lovastatin.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Lovastatin.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Lovastatin.Experimental
NilotinibThe metabolism of Nilotinib can be decreased when combined with Lovastatin.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Lovastatin.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Lovastatin.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lovastatin.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Lovastatin.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Lovastatin.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Lovastatin.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Lovastatin.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Lovastatin.Approved, Investigational
Nitric OxideThe serum concentration of Lovastatin can be increased when it is combined with Nitric Oxide.Approved
NitroaspirinThe serum concentration of Lovastatin can be increased when it is combined with Nitroaspirin.Investigational
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Lovastatin.Approved
NorfloxacinThe serum concentration of Lovastatin can be increased when it is combined with Norfloxacin.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Lovastatin.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Lovastatin.Approved
NoscapineThe serum concentration of Lovastatin can be increased when it is combined with Noscapine.Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Lovastatin.Investigational
OlanzapineThe serum concentration of Lovastatin can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Lovastatin.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Lovastatin.Vet Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Lovastatin.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Lovastatin.Approved
OmapatrilatThe serum concentration of Lovastatin can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Lovastatin.Experimental
OndansetronThe metabolism of Ondansetron can be decreased when combined with Lovastatin.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Lovastatin.Approved
OsimertinibThe serum concentration of Lovastatin can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Lovastatin.Approved
OtamixabanThe serum concentration of Lovastatin can be increased when it is combined with Otamixaban.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Lovastatin.Experimental, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Lovastatin.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Lovastatin.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Lovastatin.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Lovastatin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Lovastatin is combined with Oxycodone.Approved, Illicit, Investigational
OxymetholoneThe serum concentration of Lovastatin can be increased when it is combined with Oxymetholone.Approved, Illicit
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Lovastatin.Approved, Vet Approved
PalbociclibThe serum concentration of Lovastatin can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Lovastatin.Approved, Investigational
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Lovastatin.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Lovastatin.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Lovastatin.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Lovastatin.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Lovastatin.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Lovastatin.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Lovastatin.Approved
PazopanibLovastatin may increase the hepatotoxic activities of Pazopanib.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Lovastatin.Approved
PentobarbitalThe metabolism of Lovastatin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Lovastatin.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Lovastatin.Approved, Investigational
PerindoprilThe serum concentration of Lovastatin can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Lovastatin.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Lovastatin.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Lovastatin.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Lovastatin.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Lovastatin.Withdrawn
PhenelzineThe serum concentration of Lovastatin can be increased when it is combined with Phenelzine.Approved
PhenindioneLovastatin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Lovastatin can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Lovastatin.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Lovastatin.Approved, Investigational
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Lovastatin.Approved, Vet Approved
PhenytoinThe serum concentration of Lovastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Lovastatin can be increased when it is combined with Phosphoramidon.Experimental
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Lovastatin.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Lovastatin.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Lovastatin.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Lovastatin.Withdrawn
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Lovastatin.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Lovastatin.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Lovastatin.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Lovastatin.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Lovastatin.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Lovastatin.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Lovastatin.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Lovastatin.Approved
PosaconazoleThe serum concentration of Lovastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Lovastatin.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Lovastatin.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Lovastatin.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Lovastatin.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Lovastatin.Approved, Vet Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Lovastatin.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Lovastatin.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lovastatin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Lovastatin.Withdrawn
PrimaquineThe metabolism of Primaquine can be decreased when combined with Lovastatin.Approved
PrimidoneThe metabolism of Lovastatin can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Lovastatin can be increased when it is combined with Prinomastat.Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Lovastatin.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Lovastatin.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Lovastatin.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Lovastatin.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Lovastatin.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Lovastatin.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Lovastatin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Lovastatin.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Lovastatin.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Lovastatin.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Lovastatin.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Lovastatin.Approved, Investigational
QuinaprilThe serum concentration of Lovastatin can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Lovastatin.Approved
QuinineThe serum concentration of Lovastatin can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Lovastatin can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Lovastatin.Approved, Investigational
RacecadotrilThe serum concentration of Lovastatin can be increased when it is combined with Racecadotril.Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Lovastatin.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Lovastatin.Approved
RamelteonThe metabolism of Ramelteon can be decreased when combined with Lovastatin.Approved, Investigational
RamiprilThe serum concentration of Lovastatin can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Lovastatin can be increased when it is combined with Ranitidine.Approved
RanolazineRanolazine may increase the myopathic rhabdomyolysis activities of Lovastatin.Approved, Investigational
RavuconazoleThe risk or severity of adverse effects can be increased when Ravuconazole is combined with Lovastatin.Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Lovastatin.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Lovastatin.Approved
RemikirenThe serum concentration of Lovastatin can be increased when it is combined with Remikiren.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Lovastatin.Approved, Investigational
ResveratrolThe serum concentration of Lovastatin can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Lovastatin.Approved
RibociclibThe serum concentration of Lovastatin can be increased when it is combined with Ribociclib.Approved
RifabutinThe metabolism of Lovastatin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Lovastatin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Lovastatin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Lovastatin.Approved, Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Lovastatin.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Lovastatin.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Lovastatin.Approved
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Lovastatin.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Lovastatin.Approved, Investigational
RitonavirThe serum concentration of Lovastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Lovastatin can be increased when it is combined with Rivaroxaban.Approved
RivastigmineThe serum concentration of Lovastatin can be increased when it is combined with Rivastigmine.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Lovastatin.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Lovastatin.Approved
RolitetracyclineThe serum concentration of Lovastatin can be increased when it is combined with Rolitetracycline.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Lovastatin.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Lovastatin.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Lovastatin.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Lovastatin.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Lovastatin.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Lovastatin.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Lovastatin.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Lovastatin.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Lovastatin.Approved
RutinThe serum concentration of Lovastatin can be increased when it is combined with Rutin.Experimental, Investigational
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Lovastatin.Approved
S-3304The serum concentration of Lovastatin can be increased when it is combined with S-3304.Investigational
SafinamideThe metabolism of Safinamide can be decreased when combined with Lovastatin.Approved
SalbutamolThe serum concentration of Lovastatin can be increased when it is combined with Salbutamol.Approved, Vet Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Lovastatin.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Lovastatin.Approved
SaquinavirThe serum concentration of Lovastatin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe serum concentration of Lovastatin can be increased when it is combined with Sarilumab.Approved
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Lovastatin.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Lovastatin.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Lovastatin.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Lovastatin.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Lovastatin.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Lovastatin.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Lovastatin.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Lovastatin.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Lovastatin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Lovastatin.Approved
SiltuximabThe serum concentration of Lovastatin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Lovastatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Lovastatin.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Lovastatin.Approved, Investigational
SitagliptinThe serum concentration of Lovastatin can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Lovastatin.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Lovastatin can be increased when it is combined with Sivelestat.Investigational
Sodium bicarbonateThe serum concentration of Lovastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Lovastatin.Approved
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Lovastatin.Investigational
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Lovastatin.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Lovastatin.Approved, Investigational
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Lovastatin.Approved
SpiraprilThe serum concentration of Lovastatin can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Lovastatin can be increased when combined with St. John&#39;s Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Lovastatin can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Lovastatin.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Lovastatin.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Lovastatin.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Lovastatin.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Lovastatin.Approved
SulfanilamideThe serum concentration of Lovastatin can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Lovastatin.Approved
SulfisoxazoleThe metabolism of Lovastatin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Lovastatin.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Lovastatin.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Lovastatin.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Lovastatin.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Lovastatin.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Lovastatin.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Lovastatin.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Lovastatin.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Lovastatin.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Lovastatin.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Lovastatin.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Lovastatin.Experimental
TelaprevirThe serum concentration of Lovastatin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Lovastatin can be increased when it is combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Lovastatin.Approved
TemocaprilThe serum concentration of Lovastatin can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Lovastatin.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Lovastatin.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Lovastatin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Lovastatin.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Lovastatin.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Lovastatin.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Lovastatin.Experimental
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Lovastatin.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Lovastatin.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Lovastatin.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Lovastatin.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Lovastatin.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Lovastatin.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Lovastatin.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Lovastatin.Approved, Vet Approved
ThiopentalThe serum concentration of Lovastatin can be increased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lovastatin.Approved, Withdrawn
ThiorphanThe serum concentration of Lovastatin can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Lovastatin.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Lovastatin.Approved
TicagrelorThe serum concentration of Lovastatin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Lovastatin can be decreased when combined with Ticlopidine.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Lovastatin.Approved, Investigational
TioclomarolLovastatin may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe serum concentration of Lovastatin can be increased when it is combined with Tioconazole.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Lovastatin.Approved
TipranavirThe serum concentration of Lovastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Lovastatin can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Lovastatin.Approved, Investigational
TofisopamThe serum concentration of Lovastatin can be increased when it is combined with Tofisopam.Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Lovastatin.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lovastatin.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Lovastatin.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Lovastatin.Approved
TopiroxostatThe serum concentration of Lovastatin can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Lovastatin.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Lovastatin.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Lovastatin.Approved, Investigational
TrabectedinLovastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Lovastatin.Approved, Investigational
TrandolaprilThe serum concentration of Lovastatin can be increased when it is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Lovastatin.Approved, Investigational
TranylcypromineThe serum concentration of Lovastatin can be increased when it is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Lovastatin.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Lovastatin.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Lovastatin.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Lovastatin.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Lovastatin.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Lovastatin.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Lovastatin.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Lovastatin.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Lovastatin.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Lovastatin.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Lovastatin.Approved
TromethamineThe serum concentration of Lovastatin can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Lovastatin.Vet Approved
UbenimexThe serum concentration of Lovastatin can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Lovastatin.Approved, Investigational, Nutraceutical
UdenafilThe metabolism of Udenafil can be decreased when combined with Lovastatin.Approved, Investigational
UlinastatinThe serum concentration of Lovastatin can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Lovastatin.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Lovastatin.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Lovastatin.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Lovastatin.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Lovastatin.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Lovastatin.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Lovastatin.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Lovastatin.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Lovastatin.Approved
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Lovastatin.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Lovastatin.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Lovastatin.Approved
VerapamilThe serum concentration of Lovastatin can be increased when it is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Lovastatin.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Lovastatin.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Lovastatin.Approved
VildagliptinThe serum concentration of Lovastatin can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Lovastatin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Lovastatin.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Lovastatin.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Lovastatin.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Lovastatin.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Lovastatin.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Lovastatin.Approved
VoriconazoleThe serum concentration of Lovastatin can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Lovastatin.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Lovastatin.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Lovastatin.Approved
XimelagatranThe serum concentration of Lovastatin can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Lovastatin.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Lovastatin.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Lovastatin can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Lovastatin.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Lovastatin.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Lovastatin.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Lovastatin.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Lovastatin.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Lovastatin.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Lovastatin.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Lovastatin.Approved
ZofenoprilThe serum concentration of Lovastatin can be increased when it is combined with Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Lovastatin.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Lovastatin.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Lovastatin.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Lovastatin.Approved
ZucapsaicinThe serum concentration of Lovastatin can be increased when it is combined with Zucapsaicin.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Lovastatin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Avoid taking with grapefruit juice.
  • Take with food, 50% increase in bioavailability when taken with food.

References

Synthesis Reference

Donald F. Gerson, Xinfa Xiao, "Process for the production of lovastatin using Coniothyrium fuckelii." U.S. Patent US5409820, issued January, 1984.

US5409820
General References
  1. Bobek P, Ozdin L, Galbavy S: Dose- and time-dependent hypocholesterolemic effect of oyster mushroom (Pleurotus ostreatus) in rats. Nutrition. 1998 Mar;14(3):282-6. [PubMed:9583372]
External Links
Human Metabolome Database
HMDB14372
KEGG Drug
D00359
KEGG Compound
C07074
PubChem Compound
53232
PubChem Substance
46508223
ChemSpider
48085
BindingDB
34168
ChEBI
40303
ChEMBL
CHEMBL503
Therapeutic Targets Database
DAP000551
PharmGKB
PA450272
IUPHAR
2739
Guide to Pharmacology
GtP Drug Page
HET
803
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lovastatin
ATC Codes
C10BA01 — Lovastatin and nicotinic acidC10AA02 — Lovastatin
AHFS Codes
  • 24:06.08 — Hmg-coa Reductase Inhibitors
PDB Entries
1cqp
FDA label
Download (126 KB)
MSDS
Download (99.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentLung Inflammation1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceDrug Drug Interactions / Healthy Volunteers1
1CompletedTreatmentLipid Metabolism Disorders1
1CompletedTreatmentNeurofibromatosis 11
1CompletedTreatmentStrokes1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2TerminatedTreatmentAny Cancer / Cancer, Breast1
1, 2WithdrawnTreatmentSevere Persistent Asthma1
2Active Not RecruitingTreatmentJaundice / Rhabdomyolysis / Strokes1
2Active Not RecruitingTreatmentNeurofibromatosis Type 11
2CompletedBasic ScienceBlood Platelets Proteome1
2CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Hypercholesterolaemia / Myocardial Ischemia1
2CompletedPreventionCardiovascular Disease (CVD) / Carotid Stenosis / Cerebral Arteriosclerosis / Cerebrovascular Disorders / Heart Diseases / Vascular Diseases1
2CompletedPreventionPrecancerous Conditions / Stage 0 Melanoma / Stage I Melanoma / Stage II Melanoma1
2CompletedSupportive CareProstate Cancer1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentHIV Seropositivity1
2CompletedTreatmentRett's Syndrome1
2CompletedTreatmentRheumatoid Arthritis1
2Enrolling by InvitationTreatmentFragile X Syndrome (FXS)1
2RecruitingOtherParkinson's Disease (PD)1
2RecruitingTreatmentFragile X Syndrome (FXS)1
2RecruitingTreatmentLearning Disability / Neurofibromatosis Type 11
2TerminatedSupportive CareCancer, Breast / Radiation Toxicity1
2TerminatedTreatmentCancer, Breast1
2Unknown StatusTreatmentCancer, Ovarian1
2Unknown StatusTreatmentXanthomatosis, Cerebrotendinous1
2WithdrawnTreatmentChild Syndrome / Conradi Syndrome / Smith Lemli Opitz Syndrome / Syndromic Ichthyoses1
2WithdrawnTreatmentMalignant Melanoma / Melanoma1
2, 3CompletedTreatmentAlveolar Bone Loss, Chronic Periodontitis, Lovestatin Gel, Regeneration1
2, 3CompletedTreatmentAtherosclerosis / Coronary Artery Disease1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedPreventionHypercholesterolaemia1
3CompletedTreatmentCardiovascular Disease (CVD) / Coronary Arteriosclerosis / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedTreatmentHypercholesterolaemia1
3CompletedTreatmentIntermittent Claudication / Peripheral Vascular Disease (PVD)2
3TerminatedTreatmentHypercholesterolaemia1
4CompletedTreatmentDyslipidemias / Hyperlipidemias / Mixed hypercholesterolemia1
4CompletedTreatmentHealthy Volunteers2
4RecruitingTreatmentFragile X Syndrome (FXS) / Genetic Diseases1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHypercholesterolaemia1
Not AvailableSuspendedTreatmentProstate Cancer1

Pharmacoeconomics

Manufacturers
  • Andrx labs llc
  • Actavis elizabeth llc
  • Apotex inc
  • Carlsbad technology inc
  • Lupin ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Merck research laboratories div merck co inc
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral
Tablet, extended release; tablet, multilayer, extended releaseOral
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral60 mg/1
TabletOral20 mg
TabletOral40 mg
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
Prices
Unit descriptionCostUnit
Altoprev 60 mg 24 Hour tablet7.99USD tablet
Altoprev 60 mg tablet7.74USD tablet
Altoprev 20 mg 24 Hour tablet6.88USD tablet
Altoprev 20 mg tablet6.61USD tablet
Mevacor 40 mg tablet4.57USD tablet
Altoprev 40 mg tablet4.41USD tablet
Lovastatin 40 mg tablet4.36USD tablet
Altoprev 10 mg 24 Hour tablet3.07USD tablet
Mevacor 20 mg tablet2.53USD tablet
Lovastatin 20 mg tablet2.42USD tablet
Altocor 20 mg 24 Hour tablet2.36USD tablet
Apo-Lovastatin 40 mg Tablet2.11USD tablet
Co Lovastatin 40 mg Tablet2.11USD tablet
Mylan-Lovastatin 40 mg Tablet2.11USD tablet
Novo-Lovastatin 40 mg Tablet2.11USD tablet
Pms-Lovastatin 40 mg Tablet2.11USD tablet
Ran-Lovastatin 40 mg Tablet2.11USD tablet
Ratio-Lovastatin 40 mg Tablet2.11USD tablet
Sandoz Lovastatin 40 mg Tablet2.11USD tablet
Mevacor 10 mg tablet1.65USD tablet
Lovastatin 10 mg tablet1.37USD tablet
Apo-Lovastatin 20 mg Tablet1.14USD tablet
Co Lovastatin 20 mg Tablet1.14USD tablet
Mylan-Lovastatin 20 mg Tablet1.14USD tablet
Novo-Lovastatin 20 mg Tablet1.14USD tablet
Pms-Lovastatin 20 mg Tablet1.14USD tablet
Ran-Lovastatin 20 mg Tablet1.14USD tablet
Ratio-Lovastatin 20 mg Tablet1.14USD tablet
Sandoz Lovastatin 20 mg Tablet1.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6080428No1997-05-272017-05-27Us
US6469035No1998-03-152018-03-15Us
US6080778No1998-03-232018-03-23Us
US6485748No1997-12-122017-12-12Us
US5916595No1997-12-122017-12-12Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)174.5 °CNot Available
water solubility0.0004 mg/mLNot Available
logP4.26HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0243 mg/mLALOGPS
logP4.11ALOGPS
logP3.9ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)14.91ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area72.83 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity113.18 m3·mol-1ChemAxon
Polarizability46.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9452
Blood Brain Barrier+0.9287
Caco-2 permeable-0.5484
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor IInhibitor0.7046
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.8299
CYP450 2C9 substrateNon-substrate0.8333
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6868
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9291
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.8475
CarcinogenicityNon-carcinogens0.9519
BiodegradationNot ready biodegradable0.8819
Rat acute toxicity2.0554 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7272
hERG inhibition (predictor II)Non-inhibitor0.7484
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-2910000000-dc8caf3905a76d1dc259
GC-MS Spectrum - EI-BGC-MSsplash10-0a4j-1910000000-8aeacab386a420581150
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0k9j-0392200000-046f8ecdd9105ec8f133
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fg2-0590000000-79f2e6dc3b230361fea3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0092-0970000000-029f3798d63ab95ed321
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0592-0930000000-85de8f33dd78ba45de36
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05fv-0910000000-7a730b8fcd91e3df5b8f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000e-0590000000-2206c97b74e146b3218d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0092-1960000000-6b3a14df210273b89f18
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0592-1910000000-38bd634327305fe325cf
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0abd-1900000000-e7dab133ffe03d435831
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0536-2900000000-12e639483c7d1a83da05
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002f-2900000000-ed64daa9de830f1f3cb0

Taxonomy

Description
This compound belongs to the class of organic compounds known as delta valerolactones. These are cyclic organic compounds containing an oxan-2- one moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactones
Sub Class
Delta valerolactones
Direct Parent
Delta valerolactones
Alternative Parents
Fatty acid esters / Oxanes / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / Oxacyclic compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Delta valerolactone / Fatty acid ester / Delta_valerolactone / Dicarboxylic acid or derivatives / Oxane / Fatty acyl / Carboxylic acid ester / Secondary alcohol / Carboxylic acid derivative / Oxacycle
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
polyketide, fatty acid ester, delta-lactone, carbobicyclic compound, statin (naturally occurring) (CHEBI:40303)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Abe Y, Suzuki T, Ono C, Iwamoto K, Hosobuchi M, Yoshikawa H: Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum. Mol Genet Genomics. 2002 Jul;267(5):636-46. Epub 2002 Jun 28. [PubMed:12172803]
  2. Miyazaki A, Koieyama T, Shimada Y, Kikuchi T, Nezu H, Ito K, Kasanuki N, Koga T: Effects of pravastatin sodium on mevalonate metabolism in common marmosets. J Biochem. 2002 Sep;132(3):395-400. [PubMed:12204108]
  3. Buxbaum JD, Geoghagen NS, Friedhoff LT: Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alzheimers Dis. 2001 Apr;3(2):221-229. [PubMed:12214063]
  4. Baranova NA, Kreier VG, Egorov NS: [Concentration on Diapak C 16 capsules of lovastatin, mevinolinic acid and other inhibitors of biosynthesis of sterins produced by Penicillium citrinum 89]. Antibiot Khimioter. 2002;47(4):3-6. [PubMed:12369143]
  5. Farina HG, Bublik DR, Alonso DF, Gomez DE: Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis. 2002;19(6):551-9. [PubMed:12405293]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC: Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278 . [PubMed:19249983]
  8. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S: Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46. [PubMed:12082550]
Details
2. Integrin alpha-L
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other/unknown
General Function
Metal ion binding
Specific Function
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated ...
Gene Name
ITGAL
Uniprot ID
P20701
Uniprot Name
Integrin alpha-L
Molecular Weight
128768.495 Da
References
  1. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G, Cottens S, Weitz-Schmidt G, Hommel U: Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol. 1999 Sep 10;292(1):1-9. [PubMed:10493852]
Details
3. Histone deacetylase 2
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other
General Function
Transcription factor binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC2
Uniprot ID
Q92769
Uniprot Name
Histone deacetylase 2
Molecular Weight
55363.855 Da
References
  1. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC: Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res. 2008 Apr 1;68(7):2375-83. doi: 10.1158/0008-5472.CAN-07-5807. [PubMed:18381445]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. [PubMed:17178259]
  2. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
Has low activity towards the organophosphate paraxon and aromatic carboxylic acid esters. Rapidly hydrolyzes lactones such as statin prodrugs (e.g. lovastatin). Hydrolyzes aromatic lactones and 5- ...
Gene Name
PON3
Uniprot ID
Q15166
Uniprot Name
Serum paraoxonase/lactonase 3
Molecular Weight
39607.185 Da
References
  1. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN: Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem. 2000 Oct 27;275(43):33435-42. [PubMed:10931838]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT: Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):104-8. [PubMed:15998357]
  2. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002 May;30(5):505-12. [PubMed:11950779]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang E, Casciano CN, Clement RP, Johnson WW: HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001 Jun;18(6):800-6. [PubMed:11474784]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  3. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612]
  2. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
  2. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Ellis LC, Hawksworth GM, Weaver RJ: ATP-dependent transport of statins by human and rat MRP2/Mrp2. Toxicol Appl Pharmacol. 2013 Jun 1;269(2):187-94. doi: 10.1016/j.taap.2013.03.019. Epub 2013 Apr 2. [PubMed:23562342]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18